Sarah has over 20 years of senior-level management experience in corporate development in the biotech sector. In her previous role as Chief Scientific Officer at Adjuvant Partners, she led business development and corporate strategy for a number of clients including large cap pharmaceutical companies, biotechnology companies, technology providers, and major medical centers with a focus on cell and gene therapy. She helped found Cardiogen Sciences, Inc. (acquired in 2015 by Audentes Therapeutics) and was the Senior Director, Technology Sections at the Alliance for Regenerative Medicine including launching and managing the Gene Therapy Section and the Genome Editing Task Force. Prior to Adjuvant Partners, Sarah held the position of Vice President, Business Development for Orasi Medical, Circle Biologics and BioE.
She holds a Doctorate in molecular biology and bioethics from the University of Minnesota and a Bachelor of Science degree in biochemistry from the University of Wisconsin. From 1995-2004, she completed a post-doctoral fellowship with James Wilson in the University of Pennsylvania’s Human Gene Therapy Program focused on muscle directed gene therapy as well as served as a licensing manager for the UPENN Center for Technology Transfer. She has continued her education in the MBA program at the University of Pennsylvania’s Wharton School and currently directs the Advancement Committee and is on the Board of the Minneapolis United Soccer Club.